Strides Pharma Science Limited has confirmed that its promoters and promoter group did not encumber any shares during the financial year ended March 31, 2026. The disclosure, submitted to the stock exchanges, assures investors that no new pledges or charges were created on the promoter holdings, other than those already reported.

The declaration was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires listed companies to inform the exchanges if promoters have pledged their shares as collateral, a move that can signal financial stress or risk for shareholders.

Pronomz Ventures LLP, representing the promoters and promoter group, communicated the status to the National Stock Exchange of India Limited and BSE Limited. The firm confirmed that the shareholding remained free from fresh encumbrances throughout FY26.

The filing was signed by Chandrappa Seetharamaiah, Designated Partner of Pronomz Ventures LLP. The document was submitted to the exchanges on April 7, 2026, for their information and records.

Strides Pharma Science Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a revenue of INR48,587 million for FY26, representing a growth of 6.4% year-on-year. Adjusting for access markets facing donor funding challenges, the underlying revenue growth was approximately 10%. The Ex-U.S. markets delivered a robust 21% growth, with the business mix shifting significantly as Ex-U.S. contribution increased to approximately 46% in FY26 from 41% in FY24.

Financial Performance Overview

Profitability metrics showed strong improvement during the year. EBITDA for FY26 stood at INR925 crores, a 15% year-on-year growth, with margins expanding by 140 basis points to 19%. Operational PAT grew by 50% year-on-year to INR518 crores, crossing the INR500 crores mark for the first time. Reported PAT for the year was INR575 crores, up 40%, with a reported EPS of INR60.3 per share. Operational EPS for the year was INR56.2 per share.

Operational Efficiency and Balance Sheet

The company continued to focus on efficiency and cash generation. The EBITDA to operational PAT conversion ratio improved to 56%, while the EBITDA to operating cash conversion was 76%. The net debt-to-EBITDA ratio improved from 1.9x in the previous year to 1.55x. Return on Capital Employed (ROCE) improved to 15.76% for FY26. The net debt as of March 26 stood at INR1,437 crores. The company invested INR418 crores across tangible and intangible assets during the year.

Business Segment Performance

The U.S. business reported a revenue of $284 million for FY26. The performance was impacted by a weaker flu season in the second half and the ramp-up of controlled substances where allocations are currently building up. The company remains focused on portfolio quality, having exited 9 products that did not meet return thresholds, and continues to target a revenue range of $375 million to $400 million in the U.S.

Ex-U.S. markets showed strong traction, with Other Regulated Markets (ORM) revenues growing from $31 million in Q1 FY24 to an exit run rate of $52 million in Q4 FY26. The company also announced the acquisition of certain products from Sandoz, expected to contribute from the second half of FY27, further strengthening its presence in Africa.

The Board of Directors has recommended a dividend of INR5 per share. Additionally, the company announced the appointment of Ramaraju, current Chief Operating Officer, as an Executive Director responsible for global technical operations.